Search

Your search keyword '"ACAM2000 (Vaccine) -- Health aspects"' showing total 27 results
Start Over Descriptor "ACAM2000 (Vaccine) -- Health aspects"
27 results on '"ACAM2000 (Vaccine) -- Health aspects"'

1. Emergent BioSolutions' ACAM2000 receives FDA approval for Mpox indication

Subjects
United States. Food and Drug Administration, Drug approval -- Health aspects, Vaccines -- Health aspects, Business, News, opinion and commentary, ACAM2000 (Vaccine) -- Health aspects
Abstract

Emergent BioSolutions announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for the expansion of the indication for ACAM2000, to include prevention of mpox [...]

Published
2024

2. Emergent BioSolutions ACAM2000(r), (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions

Subjects
United States. Food and Drug Administration, Emergent BioSolutions Inc., Biotechnology industry -- Health aspects, Vaccinia -- Drug therapy -- Prevention, Drug approval -- Health aspects, Public health -- Health aspects, Smallpox -- Prevention -- Drug therapy, Smallpox vaccine -- Health aspects, General interest, News, opinion and commentary, World Health Organization, ACAM2000 (Vaccine) -- Health aspects
Abstract

GAITHERSBURG: Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expansion of the indication for [...]

Published
2024

3. FDA ROUNDUP: AUGUST 30, 2024

Subjects
United States. Food and Drug Administration, Drug approval -- Health aspects, Vaccines -- Health aspects, News, opinion and commentary, ACAM2000 (Vaccine) -- Health aspects
Abstract

Silver Spring, MD -- The following information was released by the U.S. Food and Drug Administration (FDA): Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of [...]

Published
2024

4. Emergent BioSolutions' ACAM2000(R), (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions

Subjects
United States. Food and Drug Administration, Emergent BioSolutions Inc., Biotechnology industry -- Health aspects, Vaccinia -- Health aspects, Drug approval -- Health aspects, Public health -- Health aspects, Smallpox -- Health aspects, Smallpox vaccine -- Health aspects, Banking, finance and accounting industries, Business, ACAM2000 (Vaccine) -- Health aspects
Abstract

GAITHERSBURG, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application [...]

Published
2024

5. FDA Approves Emergent BioSolutions Vaccine as New Tool in Fight Against Mpox

Author

Vinluan, Frank

Subjects
Smallpox -- Health aspects, Smallpox vaccine -- Health aspects, ACAM2000 (Vaccine) -- Health aspects
Abstract

https://medcitynews.com/2024/08/mpox-vaccine-fda-approval-emergent-biosolutions-acam2000-ebs/ Emergent BioSolutions’ smallpox vaccine, ACAM2000, now has an additional FDA approval covering mpox. It’s one of two FDA-approved mpox vaccines, joining Jynneos from Bavarian Nordic. The post https://medcitynews.com/2024/08/mpox-vaccine-fda-approval-emergent-biosolutions-acam2000-ebs/ appeared [...]

Published
2024

6. Vaccines for Monkeypox Prevention: Jynneos and ACAM2000

Author

Park, Brian and Ernst, Diana

Subjects
Human monkeypox -- Drug therapy -- Prevention, Neomycin -- Health aspects, Diseases -- Prevention -- Drug therapy, Immunodeficiency -- Drug therapy -- Prevention, Infants -- Health aspects, Smallpox vaccine -- Health aspects, Health, ACAM2000 (Vaccine) -- Health aspects
Abstract

The Food and Drug Administration (FDA) has licensed 2 vaccines for the prevention of monkeypox infection: ACAM2000 (smallpox [vaccinia] vaccine, live) and Jynneos (smallpox and monkeypox vaccine, live, nonreplicating). In [...]

Published
2022

7. Replication-Deficient Jynneos Recommended for Orthopoxvirus

Subjects
Vaccination -- Health aspects, Vaccines -- Health aspects, Health, ACAM2000 (Vaccine) -- Health aspects
Abstract

HealthDay News — The replication-deficient Vaccinia virus vaccine (Jynneos) is recommended over the replication-competent Vaccinia virus vaccine ACAM2000 for individuals with occupational exposure to orthopoxvirus, according to research published in [...]

Published
2022

8. MONKEYPOX: PHYSICIAN FREQUENTLY ASKED QUESTIONS

Subjects
United States. Centers for Disease Control and Prevention, Human monkeypox -- Health aspects, Cidofovir -- Health aspects, Infection -- Health aspects, News, opinion and commentary, ACAM2000 (Vaccine) -- Health aspects
Abstract

CHICAGO, IL -- The following information was released by the American Medical Association (AMA): Clinical questions 1. What should prompt clinical suspicion for monkeypox infection? Clinicians should be alert to [...]

Published
2022

9. Replication-Deficient JYNNEOS Recommended for Orthopoxvirus

Subjects
Vaccination -- Health aspects, Vaccines -- Health aspects, News, opinion and commentary, Sports and fitness, ACAM2000 (Vaccine) -- Health aspects
Abstract

TUESDAY, May 31, 2022 (HealthDay News) -- The replication-deficient Vaccinia virus vaccine is recommended over the replication-competent Vaccinia virus vaccine ACAM2000 for individuals with occupational exposure to orthopoxvirus, according to [...]

Published
2022

10. Emergent BioSolutions to buy smallpox vaccine business, ACAM2000 from Sanofi for $125 million

Subjects
United States. Food and Drug Administration, United States. Centers for Disease Control and Prevention, Sanofi S.A., Contract manufacturing -- Health aspects, Smallpox -- Health aspects, Smallpox vaccines -- Health aspects, Pharmaceutical industry -- Health aspects, Pharmaceuticals and cosmetics industries, ACAM2000 (Vaccine) -- Health aspects
Abstract

Emergent BioSolutions, a global life sciences company, has entered into an agreement to acquire the ACAM2000, (Smallpox (Vaccinia) Vaccine, Live) business of Sanofi in an all-cash transaction with a total [...]

Published
2017

11. Findings from United States Army Update Knowledge of Smallpox Vaccines (Povidone Iodine Ointment Application to the Vaccination Site Does Not Alter Immunoglobulin G Antibody Response to Smallpox Vaccine)

Subjects
United States. Army, Physical fitness -- Health aspects, Smallpox vaccines -- Research -- Health aspects, Medical research -- Health aspects, Biopharmaceuticals -- Research -- Health aspects, Vaccination -- Health aspects, Immunoglobulin G -- Health aspects, Health, ACAM2000 (Vaccine) -- Health aspects
Abstract

2016 AUG 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on Immunization and Public Health are presented in a new [...]

Published
2016

12. Use of vaccinia virus smallpox vaccine in laboratory and health care personnel at risk for occupational exposure to orthopoxviruses-recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015

Author

Petersen, Brett W., Harms, Tiara J., Reynolds, Mary G., and Harrison, Lee H.

Subjects
ACAM2000 (Vaccine) -- Health aspects, Dryvax (Vaccine) -- Health aspects, Vaccination -- Health aspects, Vaccinia -- Care and treatment -- Health aspects, Infection -- Care and treatment -- Health aspects, Smallpox -- Care and treatment -- Health aspects, Medical personnel -- Health aspects, Smallpox vaccine -- Health aspects, United States. Food and Drug Administration, United States. Centers for Disease Control and Prevention
Abstract

On June 25, 2015, the Advisory Committee on Immunization Practices (ACIP) recommended routine vaccination with live smallpox (vaccinia) vaccine (ACAM2000) for laboratory personnel who directly handle 1) cultures or 2) [...]

Published
2016

13. Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility

Subjects
United States. Food and Drug Administration, Smallpox -- Health aspects, Smallpox vaccines -- Health aspects, Drug approval -- Health aspects, General interest, News, opinion and commentary, ACAM2000 (Vaccine) -- Health aspects
Abstract

Rockville: Emergent Biosolutions, Inc. has issued the following press release: Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License [...]

Published
2017

14. Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility

Subjects
United States. Food and Drug Administration, Smallpox -- Health aspects, Smallpox vaccines -- Health aspects, Drug approval -- Health aspects, General interest, News, opinion and commentary, ACAM2000 (Vaccine) -- Health aspects
Abstract

Boca Raton: Emergent Capital, Inc. has issued the following press release: Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics [...]

Published
2017

15. Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility

Subjects
United States. Food and Drug Administration, Smallpox -- Health aspects, Smallpox vaccines -- Health aspects, Drug approval -- Health aspects, General interest, News, opinion and commentary, ACAM2000 (Vaccine) -- Health aspects
Abstract

Planegg, Germany : Emergent BioSolutions has issued the following press release: Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics [...]

Published
2017

16. Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility

Subjects
United States. Food and Drug Administration, Smallpox -- Health aspects, Smallpox vaccines -- Health aspects, Drug approval -- Health aspects, General interest, News, opinion and commentary, ACAM2000 (Vaccine) -- Health aspects
Abstract

Winnipeg, MB: Emergent Biosolutions has issued the following press release: Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License [...]

Published
2017

17. Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility

Subjects
United States. Food and Drug Administration, Smallpox -- Health aspects, Smallpox vaccines -- Health aspects, Drug approval -- Health aspects, General interest, News, opinion and commentary, ACAM2000 (Vaccine) -- Health aspects
Abstract

Rockville: Emergent Biosolutions, Inc. has issued the following press release: Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License [...]

Published
2017

18. Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility

Subjects
United States. Food and Drug Administration, Smallpox -- Health aspects, Smallpox vaccines -- Health aspects, Drug approval -- Health aspects, General interest, News, opinion and commentary, ACAM2000 (Vaccine) -- Health aspects
Abstract

GAITHERSBURG : Emergent BioSolutions Inc has issued the following press release: Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics [...]

Published
2017

19. Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility

Subjects
United States. Food and Drug Administration, Smallpox -- Health aspects, Smallpox vaccines -- Health aspects, Drug approval -- Health aspects, General interest, News, opinion and commentary, ACAM2000 (Vaccine) -- Health aspects
Abstract

Rockville: Emergent Biosolutions, Inc. has issued the following press release: Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License [...]

Published
2017

20. Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility

Subjects
United States. Food and Drug Administration, Smallpox -- Health aspects, Smallpox vaccines -- Health aspects, Drug approval -- Health aspects, General interest, News, opinion and commentary, ACAM2000 (Vaccine) -- Health aspects
Abstract

GAITHERSBURG: Emergent BioSolutions has issued the following news release: Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application [...]

Published
2017

21. Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility

Subjects
United States. Food and Drug Administration, Smallpox -- Health aspects, Smallpox vaccines -- Health aspects, Drug approval -- Health aspects, General interest, News, opinion and commentary, ACAM2000 (Vaccine) -- Health aspects
Abstract

Winnipeg, MB: Emergent Biosolutions has issued the following press release: Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License [...]

Published
2017

22. Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility

Subjects
United States. Food and Drug Administration, Smallpox -- Health aspects, Smallpox vaccines -- Health aspects, Drug approval -- Health aspects, General interest, News, opinion and commentary, ACAM2000 (Vaccine) -- Health aspects
Abstract

Boca Raton: Emergent Capital, Inc. has issued the following press release: Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics [...]

Published
2017

23. United States : Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility

Subjects
United States. Food and Drug Administration, Smallpox -- Health aspects, Smallpox vaccines -- Health aspects, Drug approval -- Health aspects, Business, international, ACAM2000 (Vaccine) -- Health aspects
Abstract

Emergent BioSolutions Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the manufacture of ACAM2000, (Smallpox (Vaccinia) Vaccine, Live) [...]

Published
2017

24. Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility

Subjects
United States. Food and Drug Administration, Smallpox -- Health aspects, Smallpox vaccines -- Health aspects, Drug approval -- Health aspects, General interest, News, opinion and commentary, ACAM2000 (Vaccine) -- Health aspects
Abstract

Rockville: Emergent Biosolutions, Inc. has issued the following press release: Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License [...]

Published
2017

25. Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility

Subjects
United States. Food and Drug Administration, United States. Centers for Disease Control and Prevention, Smallpox -- Health aspects, Smallpox vaccines -- Health aspects, Drug approval -- Health aspects, Banking, finance and accounting industries, Business, ACAM2000 (Vaccine) -- Health aspects
Abstract

GAITHERSBURG, Md., Nov 20, 2017 (GLOBE NEWSWIRE via COMTEX) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License [...]

Published
2017

26. Emergent BioSolutions to Acquire ACAM2000 Business From Sanofi

Subjects
United States. Food and Drug Administration, United States. Centers for Disease Control and Prevention, Sanofi S.A., Smallpox vaccines -- Health aspects, Pharmaceutical industry -- Health aspects, Banking, finance and accounting industries, ACAM2000 (Vaccine) -- Health aspects
Abstract

(GlobeNewswire) - Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement to acquire the ACAM2000, (Smallpox (Vaccinia) Vaccine, Live) business of Sanofi in an all-cash transaction [...]

Published
2017

27. Reports on Monkeypox from Southern Research Institute Provide New Insights [Treatment with the Smallpox Antiviral Tecovirimat (ST-246) Alone or in Combination with ACAM2000 Vaccination Is Effective as a Postsymptomatic Therapy for Monkeypox ...]

Subjects
Human monkeypox -- Care and treatment -- Analysis -- Health aspects, Vaccination -- Analysis -- Health aspects, Antiviral agents -- Analysis -- Health aspects, Smallpox vaccine -- Analysis -- Health aspects, Health, ACAM2000 (Vaccine) -- Health aspects
Abstract

2015 OCT 9 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators discuss new findings in Animal Diseases. According to news reporting originating from [...]

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results